We investigated the impact of serial restimulation on Her2-bridging CAR-CD19 T cells using either Raji cells (CD19-positive lymphoma) or SKOV3 cells (Her2-positive ovarian carcinoma) or both, to model in vitro the potential encounters that the CAR T cell population would undergo in the patient setting in vivo. The gene discussed is CD19; the disease is lymphoma.